PRESS RELEASE

For Immediate Release

Contact: info@globalcancertechnology.com

GCT-007 CONTINUES TO RECEIVE EXCEPTIONAL GLIOBLASTOMA PRE-CLINICAL RESULTS

GCT-007 INCREASES THE SENSITIVITY TO AN IMMUNE RESPONSE IN GLIOMA CELL LINES

San Diego, CA, March 25, 2024— Global Cancer Technology (GCT) is pleased to announce promising pre-clinical results with its proprietary PI3 Kinase inhibitor GCT-007 in treating glioblastoma (GBM). A key problem with this class of PI3K inhibitors has been elements of systemic toxicity resulting from its use. Based on the distinct mechanism by which GCT-007 causes an increase in important immune structures, experiments were performed to see if lower concentrations of GCT-007 could be used to provoke an immune response while simultaneously reducing potential toxicity. The experiments were performed by Dr. Richard Tobin and his team from CU Anschutz Medical School, Department of Surgery. The new data show that treatment with GCT-007 can increase the likelihood of an immune response to glioblastoma.

“We are delighted to see the positive effects of lowering the GCT-007 concentration in this pre-clinical study for the treatment of GBM and look forward to continuing our productive and exciting collaboration with Dr. Tobin,” said Dr. M. Karen Newell Rogers, Chief Scientific Consultant for GCT.

“We are impressed with the pre-clinical advancement of GCT-007 in glioblastoma,” commented Dr. Tobin.

“Global Cancer Technology is conducting pre-clinical studies on breast cancer and glioblastoma at the University of Colorado, and we are very pleased with the ongoing collaboration,” added John Clark, the CEO of Global Cancer Technology.

---

*Global Cancer Technology is a pre-clinical non-revenue biopharma company that is currently raising investment capital to enter a Phase 1 clinical trial {**globalcancertechnology.com**}. Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.*